Berberrubine, a Main Metabolite of Berberine, Alleviates Non-Alcoholic Fatty Liver Disease via Modulating Glucose and Lipid Metabolism and Restoring Gut Microbiota
Non-alcoholic fatty liver disease (NAFLD) is a major public health problem in many countries. Berberine (BBR) is an effective therapeutic agent in alleviating NAFLD. Berberrubine (BRB) is one of the main active metabolites of BBR, which shows significant anti-obesity and antihypoglycemic effects. Ho...
Saved in:
Published in | Frontiers in pharmacology Vol. 13; p. 913378 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
08.07.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Non-alcoholic fatty liver disease (NAFLD) is a major public health problem in many countries. Berberine (BBR) is an effective therapeutic agent in alleviating NAFLD. Berberrubine (BRB) is one of the main active metabolites of BBR, which shows significant anti-obesity and antihypoglycemic effects. However, whether BRB is responsible for the
in vivo
therapeutic effect and the underlying mechanism of BRB on NAFLD have not been elucidated. In this study, the ability of BRB to ameliorate NAFLD, together with its molecular mechanism, was investigated. The results showed that BRB treatments could significantly improve hepatic steatosis and insulin resistance in high-fat diet (HFD)–fed mice and oleic acid (OA)–treated HepG2 cells. Meanwhile, BBR and BRB treatment similarly prevented lipid accumulation by regulating the protein expression of ATGL, GK, PPARα, CPT-1, ACC1, FAS, and CD36. In addition, compared with BBR, BRB could maintain glucose homeostasis
via
GLUT2, GSK3β, and G6Pase in HFD-fed mice. Furthermore, the components of the gut microbiota in mice were analyzed by 16S rRNA gene sequencing. BBR and BRB treatment could greatly modify the structure and composition of gut microbiota. At the genus level, BBR and BRB treatment decreased
Lactobacillus
and
Romboutsia
, while BBR increased beneficial bacteria, such as
Akkermansia
and
Bacteroides
, and BRB increased beneficial bacteria, such as
Ileibacterium
and
Mucispirillum
. Altogether, both BRB and BBR were active in alleviating NAFLD
in vivo
and BRB might be used as a functional material to treat NAFLD clinically. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology These authors have contributed equally to this work Yuqian Ye, Chinese Academy of Medical Sciences and Peking Union Medical College, China Reviewed by: Yizhe Cui, Heilongjiang Bayi Agricultural University, China Yuebin Ge, South-Central University for Nationalities, China Edited by: Guoxun Chen, The University of Tennessee, Knoxville, United States |
ISSN: | 1663-9812 1663-9812 |
DOI: | 10.3389/fphar.2022.913378 |